Impact of STIs on cervical cancer screening: Prevalence of

Chlamydia (Chlamydia trachomatis) < bacterial disease Gonorrhea (Neisseria gonorrhoeae) < bacterial disease africa < location epidemiology < other screening < other

Journal

International journal of STD & AIDS
ISSN: 1758-1052
Titre abrégé: Int J STD AIDS
Pays: England
ID NLM: 9007917

Informations de publication

Date de publication:
27 Aug 2024
Historique:
medline: 27 8 2024
pubmed: 27 8 2024
entrez: 27 8 2024
Statut: aheadofprint

Résumé

Cervical cancer, primarily from HPV, is prevalent in countries like Mozambique, with HIV individuals at higher risk. The Visual Inspection with Acetic Acid (VIA) screening method can be influenced by STIs like In this cross-sectional research conducted at a DREAM program facility in Maputo from 01/07/2021 to 31/05/2022, cervical specimens were taken from VIA-positive patients. CT/NG testing was performed using the Cobas® 4800 DNA CT/NG test. Statistical analyses focused on associations and prevalence rates, considering demographic, clinical, and exposure data. Among 117 women, we observed a CT prevalence of 6.8% (8/117) and an NG prevalence of 2.6%(3/117). No significant associations between CT/NG infection rates and factors such as age, HIV status, VIA results, or high-risk HPV (hrHPV) was observed. We found a 47% prevalence of hrHPV infections among participants with cervical lesions; no significant association between hrHPV and CT/NG infections was observed. This study highlights the prevalence of CT and NG in VIA-positive women in Mozambique, emphasizing the STI burden and suggesting integration of STI screening in cervical cancer prevention strategies.

Sections du résumé

BACKGROUND BACKGROUND
Cervical cancer, primarily from HPV, is prevalent in countries like Mozambique, with HIV individuals at higher risk. The Visual Inspection with Acetic Acid (VIA) screening method can be influenced by STIs like
METHODS METHODS
In this cross-sectional research conducted at a DREAM program facility in Maputo from 01/07/2021 to 31/05/2022, cervical specimens were taken from VIA-positive patients. CT/NG testing was performed using the Cobas® 4800 DNA CT/NG test. Statistical analyses focused on associations and prevalence rates, considering demographic, clinical, and exposure data.
RESULTS RESULTS
Among 117 women, we observed a CT prevalence of 6.8% (8/117) and an NG prevalence of 2.6%(3/117). No significant associations between CT/NG infection rates and factors such as age, HIV status, VIA results, or high-risk HPV (hrHPV) was observed. We found a 47% prevalence of hrHPV infections among participants with cervical lesions; no significant association between hrHPV and CT/NG infections was observed.
CONCLUSION CONCLUSIONS
This study highlights the prevalence of CT and NG in VIA-positive women in Mozambique, emphasizing the STI burden and suggesting integration of STI screening in cervical cancer prevention strategies.

Identifiants

pubmed: 39190544
doi: 10.1177/09564624241272963
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9564624241272963

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Alberto Sineque (A)

Department of Biological Sciences, Eduardo Mondlane University, Maputo, Mozambique.

Susanna Ceffa (S)

Dream Program, Community of Sant'Egidio, Rome, Italy.

Fernanda Parruque (F)

Dream Program, Community of Sant'Egidio, Mozambique.

Giovanni Guidotti (G)

Asl Roma 1, Rome, Italy.

Cacilda Massango (C)

Dream Program, Community of Sant'Egidio, Mozambique.

Zita Sidumo (Z)

Dream Program, Community of Sant'Egidio, Mozambique.

Carla Carrilho (C)

Maputo Central Hospital, Mozambique.
Department of Pathology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.

Clara Bicho (C)

Institute for Preventive Medicine and Public Health, Institute of Environmental Health, Isamb, Faculty of Medicine, University of Lisboa, Portugal.

Ricardina Rangeiro (R)

Maputo Central Hospital, Mozambique.

Stefano Orlando (S)

Department of Biomedicine and Prevention, Torvergata University of Rome, Italy.

Cesaltina Lorenzoni (C)

Maputo Central Hospital, Mozambique.

Fausto Ciccacci (F)

Unicamillus Saint Camillus International, University of Health and Medical Sciences, Rome, Italy.

Classifications MeSH